A first-time-in-human single ascending dose trial of TRV250 for the treatment of acute migraine
Phase of Trial: Phase I
Latest Information Update: 07 Nov 2017
At a glance
- Drugs TRV 250 (Primary) ; TRV 250 (Primary)
- Indications Migraine
- Focus Adverse reactions; First in man
- 07 Nov 2017 According to a Trevena media release, based on interim results the company has expanded the study to evaluate higher doses to support future Phase 2 planning.
- 20 Jul 2017 According to a Trevena media release, results are expected in the second half of 2017.
- 04 May 2017 According to a Trevena media release, first subject has been dosed.